Parkinsn's Email List Message
Posting to the Parkinsn List is a benefit of Subscription
News-New compound improves dyskinesias in MPTP monkeys
Antiparkinsonian effect of a new selective adenosine A2A receptor
antagonist in MPTP-treated monkeys
R Grondin, PJ Bedard, H Tahar, L Gregoire, A Mori, H Kase
Neurology 1999;52:1673-1677
A new compound, KW-6002, improves dyskinesias when administered alone
and potentiates levodopa, according to this study.
MPTP-treated monkeys with dyskinesias from chronic levodopa treatment
were given either 60 or 90 mg/kg KW-6002 with or without
levodopa/benserazide. Animals were rated for locomotion, parkinsonian
disability, and dyskinesias.
KW-6002 alone at both doses stimulated locomotion to an extent similar
to levodopa/benserazide alone. Dyskinesias virtually disappeared when
KW-6002 was administered alone. When administered together, the higher
dose potentiated the effects of levodopa/benserazide by approximately
30%. Effects were maintained for the 21 days of the study.
--
Judith Richards, London, Ontario, Canada
<judithr@xxxxxxxx>
^^^
\ /
\ | / Today?s Research
\\ | // ...Tomorrow?s Cure
\ | /
\|/
```````
Parkinsn's Archive Treasures Doctors, students, patients and caregivers find current Parkinson's information such as the Algorithm, Caregivers Handbook, and talks by respected Movement Disorder Specialists.
Mail converted by MHonArc
2.6.10
Site Hosting donated by He.net
&
Grant from The Parkinson Alliance
